MaxCyte to Participate in Upcoming Investor Conferences
February 14 2022 - 8:00AM
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading
commercial cell-engineering company focused on providing enabling
platform technologies to advance innovative cell-based research as
well as next-generation cell therapeutic discovery, development and
commercialization, today announced Company management will
participate in the following virtual investor conferences:
- BIO CEO & Investor
ConferencePresentation on Tuesday, February 15th
- BTIG MedTech, Digital Health, Life
Science & Diagnostic Tools ConferenceFireside chat on Thursday,
February 17th at 3:00 p.m. Eastern Time
- Cowen Annual Healthcare
ConferenceFireside chat on Monday, March 7th at 9:50 a.m. Eastern
Time
Live and archived webcasts of the events will be
available on the “Events” section of the MaxCyte investor relations
website at https://investors.maxcyte.com/. BTIG hosted events are
intended for prospective and existing BTIG clients only. To listen
to the live event, please contact your BTIG representative with
interest.
About MaxCyte
MaxCyte is a leading commercial cell-engineering
company focused on providing enabling platform technologies to
advance innovative cell-based research as well as next-generation
cell therapeutic discovery, development and commercialization. Over
the past 20 years, we have developed and commercialized our
proprietary Flow Electroporation® platform, which facilitates
complex engineering of a wide variety of cells. Our ExPERT™
platform, which is based on our Flow Electroporation technology,
has been designed to support the rapidly expanding cell therapy
market and can be utilized across the continuum of the high-growth
cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™, GTx™, and VLx™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
MaxCyte Contacts:
US IR AdviserGilmartin GroupDavid
Deuchler, CFA |
+1
415-937-5400ir@maxcyte.com |
Nominated Adviser and
Joint Corporate BrokerPanmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden |
+44 (0)20 7886 2500 |
|
|
UK IR
AdviserConsilium Strategic
CommunicationsMary-Jane ElliottChris Welsh |
+44 (0)203 709
5700maxcyte@consilium-comms.com |
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024